CDMO Services
- Home
- Therapeutic Solutions
- CDMO Services
Pioneering Patented Plant-Based Molecules at Industrial Scale
BioHarvest’s breakthrough Botanical Synthesis technology enables partnering companies to own patented plant-based small and complex molecules for the first time in history. Our B2B CDMO Division can now develop unique, protected compounds with unprecedented purity and consistency – creating powerful barriers to entry for partner products.
Our CDMO platform transforms traditional botanical production into a precise science. By optimizing plant cells in controlled environments, BioHarvest creates novel, patentable compounds that were previously impossible to produce at commercial scale. This isn’t just manufacturing – it’s the future of botanical intellectual property.
Partners gain exclusive rights to unique molecules through BioHarvest’s phase by phase development process and licensing model, enabling true product differentiation backed by patent protection. We provide a clear pathway from initial concept through commercial production, allowing partners to create their own proprietary botanical compounds.
BioHarvest Sciences Botanical Synthesis CDMO has the Potential to Become an Emerging Force in Plant-based Biologics
Tate & Lyle and BioHarvest Announce Partnership to Drive the Future of Ingredients through Botanical Synthesis Technology
In December 2024, BioHarvest Sciences and Tate & Lyle, a world leader in ingredient solutions for healthier and tastier food and beverages, announced a new partnership to develop the next-generation of proprietary plant-based molecules to address increasing consumer desire for affordable, nutritious and more sustainable plant-derived food and beverage ingredients.
This CDMO Services project will focus on developing the next generation of sweeteners – botanical sweetening ingredients using plant-derived molecules- to meet consumer desire for a sugar-like taste – with no after-taste – and enable a wider population to have more choice when it comes to accessing healthier ingredients in products.
The Biologics+ CDMO Services Offering
- Expansion into the contract development & manufacturing organization (CDMO) market is built upon the success of our commercially validated botanical synthesis technology process
- The CDMO Services division enables BioHarvest to offer disruptive innovation via Botanical Synthesis for market leaders in cosmeceutical, nutraceutical & food nutrition verticals with unique plant molecules and compounds
- Development of plant-based Biologics+ compounds creates a safer, faster and less expensive pipeline of molecules for next-generation therapeutics vs existing small and complex molecule solutions available to pharma.
- CDMO partners own all IP rights to the new developed compounds
- Biologics+ can be pursued through full FDA-approved drugs in both regulatory approval pathways: Biological drugs and Botanical drugs
- CDMO unit provides BioHarvest a unique optionality on top of existing high performing products business
Staged Gate Development Approach to Ensure Success
Development Timeline: 18-27 Months
Non-Recurring Engineering (NRE) Costs: $2.5M – $3.0M, paid for by CDMO partner
- Discovery Stage is now available for partners seeking to match plant compound candidates with their targeted indications
- Stage 1 begins with customer initiation where specific plant and compounds are chosen; cell culture development and elicitation completed
- Within 6-9 months customer can receive kilograms of molecules for development and clinical trials
- Development completes with industrial production of chosen compound and royalty model put into place with customer (expected to be ~80% gross margins)
Current Status of CDMO Compounds in Development
Botanical Synthesis Lab-to-Customer Process in Full Effect
Demand Centers and Addressable Market
CDMO Building Blocks for Growth
